Literature DB >> 3334951

Reversible ocular toxicity related to tamoxifen therapy.

A R Ashford1, I Donev, R P Tiwari, T J Garrett.   

Abstract

A 42-year-old woman with metastatic breast cancer developed bilateral optic disc swelling, retinal hemorrhages, and visual impairment three weeks after starting treatment with low doses of tamoxifen. Neurologic evaluation failed to provide an explanation for the ocular findings which resolved completely after cessation of tamoxifen therapy. This case suggests that tamoxifen has the potential for causing serious ophthalmologic toxicity which may be reversible if recognized early.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3334951     DOI: 10.1002/1097-0142(19880101)61:1<33::aid-cncr2820610107>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Electrophysiological evaluation of visual pathways in paclitaxel-treated patients.

Authors:  V Scaioli; A Caraceni; C Martini; S Curzi; G Capri; G Luca
Journal:  J Neurooncol       Date:  2005-08-25       Impact factor: 4.130

Review 2.  Systemic adjuvant therapy for node-negative breast cancer.

Authors:  A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

Review 3.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

4.  [Tamoxifen retinopathy: a case series of clinical and functional data].

Authors:  C Ritter; A B Renner; J Wachtlin; N E Bechrakis; L Krause
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

5.  Phase I trial of droloxifene in patients with metastatic breast cancer.

Authors:  A U Buzdar; S Kau; G N Hortobagyi; R L Theriault; D Booser; F A Holmes; R Walters; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 7.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

Review 8.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

9.  Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.

Authors:  Alvin Eisner; Maureen D Toomey; Julie Falardeau; John R Samples; John T Vetto
Journal:  Breast Cancer Res Treat       Date:  2007-01-27       Impact factor: 4.872

10.  Evaluation of Optic Nerve Head Parameters and Electro-Physiology Among Breast Cancer Patients on Tamoxifen.

Authors:  Qi Zhe Ngoo; Wan Hazabbah Wan Hitam; Chai Lee Tan; Venkata Murali Krishna Bhavaraju
Journal:  Cureus       Date:  2022-01-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.